Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor

Fig. 1

Enrollment of patients with concomitant type-2 diabetes mellitus (T2DM) and peripheral artery disease (PAD). From May 1, 2016 to December 31, 2017, a total of 11,431 patients with T2DM and comorbid PAD treated with sodium-glucose co-transporter-2 inhibitors (SGLT2i) and 11,431 1:1 propensity score matched patients treated with dipeptidyl peptidase-4 inhibitors (DPP4i) were enrolled in the present study. Abbreviations: DPP4i dipeptidyl peptidase-4 inhibitor, PAD peripheral artery disease; SGLT2i sodium-glucose co-transporter-2 inhibitor, T2DM type 2 diabetes mellitus

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840